Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1009-1022
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1009
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1009
Table 5 Side-effects reported
| Total, n = 94 (%) | |
| Reason for termination of treatment | |
| Completed as planned | 74 (79) |
| Adverse event | 11 (12) |
| Fatigue | 5 (5) |
| Tumor progression | 2 (2) |
| Patient preference | 1 (1) |
| Other | 1 (1) |
| Bone marrow toxicity | |
| Hemoglobin | |
| Any grade | 16 (17) |
| ≥ grade 3-4 | 0 |
| White blood cell count | |
| Any grade | 20 (21) |
| ≥ grade 3-4 | 15 (16) |
| Neutrophil count | |
| Any grade | 19 (20) |
| ≥ grade 3-4 | 19 (20) |
| Grade missing | 1 |
| Platelet count | |
| Any grade | 2 (2) |
| ≥ grade 3-4 | 0 |
| Unplanned hospitalization under and within 30 d after chemotherapy | 24 (26) |
| Febrile neutropenia | 20 (21) |
- Citation: Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Åvall-Lundqvist E, Elander NO. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol 2021; 12(11): 1009-1022
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1009.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1009